Treated and Untreated Mice RNAseq Readcount files
Epilepsy is a common neurological disease; however, few if any of the currently marketed antiseizure medications prevent or cure epilepsy. Angiotensin receptor blockers (ARBs) represent a promising strategy to treat the numerous detrimental consequences of epileptogenesis.
Scn8a pathology mimics the known effects of angiotensin type 1 receptor (AT1R) overstimulation and thus, blocking AT1R activation has potential therapeutic value in this model and other neurological disorders with similar pathological features.
Results of testing candesartan, an FDA-approved ARB used to treat hypertension in pediatric patients older than 1 year, on this transgenic Scn8a mouse model yield strong evidence for its efficacy and support its use in clinical trials for children with SCN8A-related epilepsy
For inquiries regarding the contents of this dataset, please contact the Corresponding Author listed in the README.txt file. Administrative inquiries (e.g., removal requests, trouble downloading, etc.) can be directed to data-management@arizona.edu
Funding
Translational Research Grant from the American Heart Association (19TPA34910113)
Statins Require Endogenous Blood-Brain Barrier Transporters to Confer Neuroprotective Effects in Stroke.
American Heart Association
Find out more...